Patents Assigned to National Institutes of Health
  • Patent number: 11872394
    Abstract: Described herein are systems and methods for the treatment of pain using electrical nerve conduction block (ENCB). Contrary to other methods of pain treatment, the ENCB can establish a direct block of neural activity, thereby eliminating the pain. Additionally, the ENCB can be administered without causing electrochemical damage. An example method can include: placing at least one electrode contact in electrical communication with a region of a subject's spinal cord; applying an electrical nerve conduction block (ENCB) to a nerve in the region through the at least one electrode contact; and blocking neural activity with the ENCB to reduce the pain or other unwanted sensation in the subject.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: January 16, 2024
    Assignees: CASE WESTERN RESERVE UNIVERAITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
    Inventors: Niloy Bhadra, Narendra Bhadra, Kevin L Kilgore, Scott Lempka, Jesse Wainright, Tina Vrabec, Manfred Franke
  • Patent number: 11845955
    Abstract: The present disclosure relates to a simple, fast, and low cost method for 3D microvascular imaging, termed “scatter labeled imaging of microvasculature in excised tissue” (SLIME). The method can include perfusing a contrast agent through vasculature of a tissue sample. The contrast agent can include colloids and a dispersant. After the contrast agent is perfused through the vasculature, the vasculature of the tissue sample can be treated with a molecule that cross links with at least a portion of the dispersant to form a sticky, non-Newtonian polymer that prevents leakage of the contrast agent out of the vasculature of the tissue sample. The tissue sample can then be immersed in a solution comprising a clearing agent and subsequently imaged.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: December 19, 2023
    Assignees: CASE WESTERN RESERVE UNIVERSITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
    Inventors: Michael W. Jenkins, Yehe Liu
  • Patent number: 11771749
    Abstract: The present disclosure provides compositions and methods of eliciting an anti-tumor immune response and treating cancer comprising at least one peptide of KRAS.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: October 3, 2023
    Assignees: The Medical College of Wisconsin, Inc., National Institutes of Health (NIH)
    Inventors: Jing Pan, Ming You, Ronald Lubet
  • Patent number: 11708612
    Abstract: Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment. Provided herein are methods of detecting gene expression in T cells and in monocytes as well as measuring relative abundance of particular immune cell populations and determining responsiveness to anticancer immunotherapy.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: July 25, 2023
    Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
    Inventors: Andrea Bild, Jason I. Griffiths
  • Patent number: 11701361
    Abstract: Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: July 18, 2023
    Assignees: NATIONAL INSTITUTES OF HEALTH (NCH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR), THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: John Cambier, Elizabeth Franks
  • Publication number: 20230203101
    Abstract: The present invention relates to a recombinant spike protein of the COVID-19 virus forming a trimer and a method for mass-producing the recombinant spike protein, and more specifically to a method for designing a recombinant gene expressing a recombinant spike protein of the COVID-19 virus forming a trimer for the purposes of enhancing immunogenicity and effective antigen delivery, and a method for mass-producing the recombinant spike protein in plants.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 29, 2023
    Applicants: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION, KOREA NATIONAL INSTITUTE OF HEALTH, BIOAPPLICATIONS INC
    Inventors: In Hwan HWANG, Shijian SONG, Rezaul Islam Khan MD, Haiping DIAO, Eun Ju SOHN, Bo Hwa CHOI, Jang Hoon CHOI, Eun Young JANG, Young Jae LEE
  • Patent number: 11666569
    Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 6, 2023
    Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENT
    Inventors: Sergio A. Gradilone, Nicholas F. LaRusso
  • Publication number: 20230146286
    Abstract: Biomarkers for diagnosing the disease activity, disease severity or disease type of severe cutaneous adverse drug reactions (SCARs) such as drug-induced hypersensitivity syndrome and Stevens-Johnson syndrome/toxic epidermal necrolysis are provided. Also provided is a method of testing SCARs, comprising measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in a sample derived from a subject.
    Type: Application
    Filed: April 15, 2021
    Publication date: May 11, 2023
    Applicants: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES, TOSOH CORPORATION
    Inventors: Yoshiro SAITO, Ryosuke NAKAMURA, Noriaki ARAKAWA, Yasuo OHNO, Takashi IZUMI, Motonobu SATO, Takayoshi NISHIYA, Michiko AIHARA
  • Patent number: 11627907
    Abstract: An intracellular monitoring device (IMD) that fits completely inside a living cell, and causes no significant impairment, to a cell's normal biological processes. The IMD monitors a cell for its level of a biological substance (e.g., calcium ion concentration) of interest. If the biological substance reaches or exceeds a threshold, the IMD transmits an electromagnetic signal, received by an antenna outside the cell. Each IMD has its electromagnetic signal encoded with a unique frequency. Detection of the frequency components, in the signals received by an antenna, permits identification of the source IMD's. A high calcium ion concentration is indicative of a strongly-activated cerebral cortex neuron. Brain tissue is relatively transparent to near infrared, making it a good frequency band, for the electromagnetic signals from neuron-monitoring IMD's. The near infrared of each IMD can be produced by quantum dots, powered by bioelectric catalysis triggered by high calcium ion concentration.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: April 18, 2023
    Assignees: National Institutes of Health, Office of Technology Transfer, Galiana Technology Inc.
    Inventors: Bruce T Hope, Mark A Wells, Gregory D Sutton
  • Patent number: 11612619
    Abstract: Compositions, methods, and systems for modifying sterol metabolism in a subject is disclosed. In some embodiments, the subjects may be administered one or more mammalian cells modified to express at least one sterol degrading enzyme derived from a bacterium. In many embodiments, the cell is a macrophage or monocyte stably expressing three or more enzymes that aid in opening the ? ring of cholesterol. The disclosed compositions and methods may be useful in lowering cholesterol levels in a subject in need thereof. In some embodiments, the subject may have a genetic predisposition to atherosclerosis.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: March 28, 2023
    Assignee: National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
    Inventors: Richard Eric Honkanen, Brandon Marshall D'Arcy, Mark Raymond Swingle
  • Patent number: 11555818
    Abstract: The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: January 17, 2023
    Assignee: The USA, as represted by the Secretary, Dept. of and Human Services, National Institutes of Health
    Inventors: Majda Haznadar, Ewy Mathe, Andrew D. Patterson, Curtis Craig Harris, Frank Gonzalez, Kristopher Krausz, Soumen Manna
  • Patent number: 11505559
    Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 22, 2022
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, YALE UNIVERSITY
    Inventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov, Vasilis Vasiliou
  • Publication number: 20220334121
    Abstract: Among the various aspects of the present disclosure is the provision of methods for detecting cancer in Neurofibromatosis Type 1 (NF1) patients.
    Type: Application
    Filed: January 27, 2022
    Publication date: October 20, 2022
    Applicants: Washington University, NATIONAL INSTITUTES OF HEALTH
    Inventors: Aadel Chaudhuri, Paul Jones, Jeffrey Szymanski, Angela Hirbe, Russell Sundby, John Shern
  • Patent number: 11474097
    Abstract: A cell-based quantitative high-throughput screening assay to monitor the formation of PFK1-mEGFP clusters by the action of small molecules to identify small molecules that promote intracellular PFK1 clustering in a cell cycle-dependent manner and may be used to treat cancer.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 18, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY, NATIONAL INSTITUTES OF HEALTH
    Inventors: Songon An, Danielle L. Schmitt, James Inglese, Patricia Dranchak
  • Publication number: 20220299523
    Abstract: A highly sensitive allergen measurement method is provided. A method for detecting an allergen in a sample, comprising: treating a sample with a protease; and detecting presence or absence of an allergen marker in the enzyme-treated sample by analysis that utilizes chromatographic separation. The allergen comprises buckwheat and wheat.
    Type: Application
    Filed: July 9, 2020
    Publication date: September 22, 2022
    Applicants: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES, NISSHIN SEIFUN GROUP INC.
    Inventors: Hiroshi AKIYAMA, Hiroyuki KIKUCHI, Yusuke SEKI, Chisato ARIMOTO
  • Publication number: 20220175986
    Abstract: Disclosed herein is a method for decontaminating an object to be treated by reducing the activity of endotoxin in a simple manner. The decontamination method includes a step (a) of irradiating an object to be treated with ultraviolet light of a wavelength of less than 200 nm to reduce activity of endotoxin attached to the object to be treated.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 9, 2022
    Applicants: Ushio Denki Kabushiki Kaisha, Director General of National Institute of Health Sciences
    Inventors: Hiroko MATSUMOTO, Makoto YAMANAKA, Fumitoshi TAKEMOTO, Kenji HATAKEYAMA, Yuji HAISHIMA, Yukiko KUDO, Yutaka KIKUCHI, Chie FUKUI
  • Patent number: 11351185
    Abstract: A pharmaceutical composition containing any one or more of 4?-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: June 7, 2022
    Assignees: ASCLEA CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
    Inventors: Enhong Jiang, Zhengping Zhuang, Jing Cui
  • Patent number: 11337753
    Abstract: The disclosure provides various embodiments of systems to facilitate the cutting of luminal tissue structures percutaneously.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: May 24, 2022
    Assignees: Telltale LLC, The National Institutes of Health (NIH)
    Inventors: Nasser Rafiee, Robert J Lederman, Rany Busold, Morgan House, Jaffar Khan, Toby Rogers, Christopher G Bruce
  • Publication number: 20220112179
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 14, 2022
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human Servi, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • Patent number: 11293859
    Abstract: A fermentation state monitoring apparatus includes: a terahertz wave generation element that outputs inspection light using a terahertz wave to a fermented food under fermentation in a sealed product container; a terahertz wave detection element that detects return light of the inspection light reflected by the fermented food in the product container; and a determination unit that determines a fermentation progress of the fermented food based on an index value including a reflectance of the return light with respect to the inspection light or an absorption coefficient of the return light with respect to the inspection light.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: April 5, 2022
    Assignees: HAMAMATSU PHOTONICS K.K., National Institute of Health Sciences
    Inventors: Kouichiro Akiyama, Kazuki Horita, Hironori Takahashi, Hiroshi Satozono, Tomoaki Sakamoto